Abbott Laboratories stock trades 18.37 percent below its 52-week high
Published on 10/27/2026 at 16:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and market position
- BTIG lowered its Abbott target to USD 125.00 from USD 134.00 on October 22, 2026.
- Abbott Laboratories stock stood 18.37 percent below its EUR 113.36 52-week high on October 27, 2026.
- Abbott Laboratories stock cost EUR 92.54 at Lang & Schwarz on October 27, 2026 at 4:35 p.m. CET, 0.98 percent below the Xetra close of October 26, 2026.
- Abbott had a market capitalization of USD 178.7 billion on October 27, 2026.
Abbott Laboratories (ISIN US0028241000) was trading at EUR 92.54 at Lang & Schwarz on October 27, 2026 at 4:35 p.m. CET, 0.98 percent below the 52-week high of EUR 113.36. On October 22, 2026, BTIG analyst Marie Thibault lowered the price target to USD 125.00 from USD 134.00 while keeping a Buy rating, as Markets Insider reported.
Analyst target moves lower
The BTIG change puts the target 35.08 percent above the euro quote only after converting currencies, so the two price levels are not directly comparable. In its report, the firm linked the revision to a strategic move involving Abbott's nutrition business and to a lower sales outlook, while retaining its Buy rating.
Stock remains below its high
The euro quotation stood within a 52-week range of EUR 70.10 to EUR 113.36 on October 27, 2026. That placed the stock 31.99 percent above its 52-week low and 18.37 percent below its high. The primary exchange is the NYSE, where Abbott was last quoted at USD 103.25 on October 27, 2026 at 11:41 a.m. ET. Its market capitalization was USD 178.7 billion and its price-to-earnings ratio was 38.25.
Third-quarter figures add detail
Abbott had reported third-quarter results on October 21, 2026. Sales reached USD 13.01 billion, up 14.50 percent from USD 11.37 billion a year earlier, while GAAP diluted earnings per share were USD 0.53 and adjusted diluted earnings per share were USD 1.42, according to PR Newswire. The adjusted figure excluded specified items, including USD 841.0 million of intangible amortization and USD 670.0 million linked to legal settlements.
Dividend supports the valuation
Abbott's board had declared a quarterly dividend of USD 0.63 per share on September 17, 2026, payable on November 16, 2026, according to the company release. The finance profile showed a trailing dividend yield of 2.00 percent, while the latest price-to-earnings ratio stood at 38.25. These figures leave the stock priced for continued earnings execution rather than a simple income strategy.
Euro quote below the annual high
The current euro quote was EUR 0.92 below the Xetra close of EUR 93.46 from October 26, 2026. Abbott's healthcare portfolio spans diagnostics, medical devices, nutrition and branded generic medicines.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories market data
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 27, 2026, 4:35 p.m. CET): EUR 92.54
- Change versus Xetra close: minus 0.98 percent
- Xetra close (October 26, 2026): EUR 93.46
- Market capitalization: USD 178.7 billion (as of October 27, 2026)
- 52-week range: EUR 70.10-EUR 113.36 (as of October 27, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
Market context: Market report S&P 500.
